Environmentally-friendly pharmaceutical synthesis

点击翻译按钮获取中文摘要

The proposed research creates a new collaborative relationship between Pfizer Montreal, a Canadian subsidiary**of the global pharmaceutical manufacturer Pfizer, Inc., and the mechanochemistry and green chemistry research**group of Prof. Tomislav Friscic at McGill University. Pfizer Montreal is actively looking to develop routes that**would make the manufacture of active pharmaceutical ingredients (APIs) simpler and more**environmentally-friendly. Of particular interest in that context is mechanochemical solvent-free synthesis that**should enable the use of solvents, which are a major reason for cost and environmental concern, to be greatly**diminished or completely eliminated from pharmaceutical synthesis. However, at this point Pfizer Montreal**does not have sufficient chemistry expertise to continue the development of solvent-free, mechanochemical**manufacturing and for that reason is looking to collaborate with a leading expert in the field. Pfizer Montreal**strongly believes that the collaboration with the Friscic group at McGill University, who are leaders in**solvent-free pharmaceutical synthesis and materials science, will enable them to overcome the hurdles**encountered in the development of cleaner, safer and more efficient manufacturing routes.